 Denali Therapeutics initiated a phase 3 study, using BIIB122 for the treatment of Parkinsons Disease patients with the pathogenic mutation of LRRK2, in October of 2022. The company initiated a phase 2b study, using BIIB122 for the treatment of early-stage Parkinsons Disease patients, in May of 2022. 